HOMAGE
Research type
Research Study
Full title
Bioprofiling response to mineralocorticoid receptor antagonists for the prevention of heart failure. A proof of concept clinical trial within the EU FP 7 “HOMAGE” programme « Heart OMics in AGing
IRAS ID
177553
Contact name
John Cleland
Contact email
Sponsor organisation
ACS Biomarker
Eudract number
2015-000413-48
Duration of Study in the UK
1 years, 6 months, 0 days
Research summary
Despite advances in care, prognosis remains poor once overt Heart Failure (HF) has developed. Prevention is most efficient when directed toward patients at risk and when mechanistically targeted to patients most likely to respond. We are conducting a research study to investigate whether specialised blood tests can identify the risk for developing serious heart problems. Also we would like to know whether a medicine called spironolactone can reduce that risk.
Spironolactone has been used for many years to treat high blood pressure. We want to find out if spironolactone can also slow deterioration of the heart and blood vessels.
Spironolactone helps the body get rid of salt (otherwise know as sodium) but retains potassium ions and lowers blood pressure. It may also have other effects that help maintain the health of heart muscle and blood vessels. However, spironolactone may only work for some people. The aim of this study is to develop new blood tests that can predict which people might benefit from spironolactone and which people might be at higher risk of side-effects.
REC name
North West - Greater Manchester Central Research Ethics Committee
REC reference
16/NW/0012
Date of REC Opinion
19 Feb 2016
REC opinion
Further Information Favourable Opinion